134 related articles for article (PubMed ID: 24721727)
1. Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Tang Z; Niu S; Liu F; Lao K; Miao J; Ji J; Wang X; Yan M; Zhang L; You Q; Xiao H; Xiang H
Bioorg Med Chem Lett; 2014 May; 24(9):2129-33. PubMed ID: 24721727
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Li X; Wu C; Lin X; Cai X; Liu L; Luo G; You Q; Xiang H
Eur J Med Chem; 2019 Jan; 161():445-455. PubMed ID: 30384047
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
Luo G; Tang Z; Lao K; Li X; You Q; Xiang H
Eur J Med Chem; 2018 Apr; 150():783-795. PubMed ID: 29587221
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents.
Tang Z; Wu C; Wang T; Lao K; Wang Y; Liu L; Muyaba M; Xu P; He C; Luo G; Qian Z; Niu S; Wang L; Wang Y; Xiao H; You Q; Xiang H
Eur J Med Chem; 2016 Aug; 118():328-39. PubMed ID: 27176944
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents.
Liu L; Tang Z; Wu C; Li X; Huang A; Lu X; You Q; Xiang H
Bioorg Med Chem Lett; 2018 Apr; 28(6):1138-1142. PubMed ID: 29482944
[TBL] [Abstract][Full Text] [Related]
6. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
9. Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
Burks HE; Abrams T; Kirby CA; Baird J; Fekete A; Hamann LG; Kim S; Lombardo F; Loo A; Lubicka D; Macchi K; McDonnell DP; Mishina Y; Norris JD; Nunez J; Saran C; Sun Y; Thomsen NM; Wang C; Wang J; Peukert S
J Med Chem; 2017 Apr; 60(7):2790-2818. PubMed ID: 28296398
[TBL] [Abstract][Full Text] [Related]
10. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
11. Estrogen Receptor α (ERα)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity.
Guo WY; Zeng SM; Deora GS; Li QS; Ruan BF
Curr Top Med Chem; 2019; 19(15):1318-1337. PubMed ID: 31215379
[TBL] [Abstract][Full Text] [Related]
12. Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2-mediated pathway in breast cancer.
Balakrishnan S; Bhat FA; Raja Singh P; Mukherjee S; Elumalai P; Das S; Patra CR; Arunakaran J
Cell Prolif; 2016 Dec; 49(6):678-697. PubMed ID: 27641938
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis and Evaluation of 5-pyridin-4-yl-2-thioxo-[1,3,4]oxadiazol-3-yl Derivatives as Anti-angiogenic Agents Targeting VEGFR-2.
Bhanushali U; Kalekar-Joshi S; Kulkarni-Munshi R; Yellanki S; Medishetty R; Kulkarni P; Chelakara RS
Anticancer Agents Med Chem; 2017; 17(1):67-74. PubMed ID: 27141880
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM
Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
16. Designer interface peptide grafts target estrogen receptor alpha dimerization.
Chakraborty S; Asare BK; Biswas PK; Rajnarayanan RV
Biochem Biophys Res Commun; 2016 Sep; 478(1):116-122. PubMed ID: 27462021
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents.
Devegowda PS; Balaji KS; Prasanna DS; Swaroop TR; Kameshwar VH; Jayarama S; Siddalingaiah L; Rangappa KS
Anticancer Agents Med Chem; 2018 Feb; 17(14):1931-1941. PubMed ID: 28403784
[TBL] [Abstract][Full Text] [Related]
18. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
20. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
